Associate Professor of Surgery
Dr. Beasley is an associate professor of surgery in the division of Surgical Oncology at Duke University with a secondary appointment as associate professor in the department of medicine. After playing 3 years in the women’s NBA, she began medical school. She obtained her MD (2008) and Masters of Health Science in clinical research (2010) from Duke University School of Medicine. She then completed general surgical residency at Duke University in 2015, during which time she was awarded a traineeship under a long-standing Surgical Oncology T32 grant. She then completed a fellowship in complex surgical oncology at the Ohio State University in 2017. She returned to Duke in 2017 as a faculty member. In 2019, she became co-director of the Duke Melanoma Program.
Dr. Beasley is a surgeon scientist with active involvement in clinical and translational research. Her main clinical and research interests include immunologic aspects of melanoma including oncolytic viral therapy. She is principal investigator of over 10 therapeutic clinical trials in melanoma including novel intratumoral therapies. Her research focuses on the role of innate immunity in the anti-tumor response. She has authored over 100 publications centered on melanoma. She has received multiple internal and external funding including the Society of Surgical Oncology’s Young Investigator Award, NIH K08 mentored physician scientist award, and Melanoma Research Alliance Grant.. Most recently she was selected to Duke Medical School’s Alpha Omega Alpha and received the American Society for Clinical Investigation Young Physician-Scientist Award.
Appointments and Affiliations
- Associate Professor of Surgery
- Associate Professor in Medicine
- Member of the Duke Cancer Institute
Contact Information
- Office Location: Dept of Surgery, Durham, NC 27710
- Email Address: georgia.beasley@duke.edu
Education
- B.A. Duke University, 2001
- M.D. Duke University, School of Medicine, 2008
- M.H.S. Duke University, 2012
- Duke University, 2015
- Ohio State University, 2017
Representative Publications
- Zager, Jonathan S., Marlana Orloff, Pier Francesco Ferrucci, Junsung Choi, David J. Eschelman, Evan S. Glazer, Aslam Ejaz, et al. “Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.” Ann Surg Oncol 31, no. 12 (November 2024): 8262–63. https://doi.org/10.1245/s10434-024-15886-6.
- Liu, Winston W., Olivia S. Jew, Kristen E. Rhodin, Jay S. Lee, Georgia M. Beasley, and Melodi Javid Whitley. “Hispanic patients with Merkel cell carcinoma have lower mortality compared to non-Hispanic patients in the National Cancer Database.” J Am Acad Dermatol 91, no. 4 (October 2024): 750–53. https://doi.org/10.1016/j.jaad.2024.05.089.
- Therien, A. D., C. M. Chime-Eze, K. E. Rhodin, and G. M. Beasley. “Neoadjuvant therapy for melanoma: past, present, and future.” Surgical Oncology 56 (October 1, 2024). https://doi.org/10.1016/j.suronc.2024.102127.
- Zager, Jonathan S., Marlana Orloff, Pier Francesco Ferrucci, Junsung Choi, David J. Eschelman, Evan S. Glazer, Aslam Ejaz, et al. “Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.” Ann Surg Oncol 31, no. 8 (August 2024): 5340–51. https://doi.org/10.1245/s10434-024-15293-x.
- Plebanek, Michael P., Yue Xue, Y-Van Nguyen, Nicholas C. DeVito, Xueying Wang, Alisha Holtzhausen, Georgia M. Beasley, Balamayooran Theivanthiran, and Brent A. Hanks. “A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression.” Sci Immunol 9, no. 95 (May 10, 2024): eadi4191. https://doi.org/10.1126/sciimmunol.adi4191.